Published in Sci Transl Med on April 09, 2014
Does the immune system naturally protect against cancer? Front Immunol (2014) 1.02
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Cancers Related to Immunodeficiencies: Update and Perspectives. Front Immunol (2016) 0.75
Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. Immunology (2015) 0.75
NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline. JCI Insight (2016) 0.75
T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. J Immunol (2016) 0.75
Post-transcriptional regulation of cytokine and growth factor signaling in cancer. Cytokine Growth Factor Rev (2016) 0.75
p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. Oncoimmunology (2016) 0.75
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. Front Pharmacol (2016) 0.75
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell (1986) 36.96
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (2006) 22.61
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol (1988) 16.82
AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci (1995) 14.81
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Res (2005) 7.24
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev (2005) 5.51
ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 5.42
Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 4.69
Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J (2004) 4.45
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics (2008) 3.62
Ending the message: poly(A) signals then and now. Genes Dev (2011) 3.47
A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A (1994) 3.33
Gammadelta T cells and the lymphoid stress-surveillance response. Immunity (2009) 3.23
Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol (2008) 3.14
Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 2.98
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature (2003) 2.77
The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem (2004) 2.36
Promiscuity and the single receptor: NKG2D. Nat Rev Immunol (2007) 2.27
NKG2D ligands in tumor immunity. Oncogene (2008) 2.26
Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J (1996) 1.96
Modulation of natural killer cells by human cytomegalovirus. J Clin Virol (2008) 1.90
Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A (2008) 1.80
Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat (2012) 1.77
Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res (1976) 1.70
Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med (2013) 1.69
Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64
Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun (2006) 1.62
Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol (2005) 1.54
Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol (2003) 1.53
Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med (2013) 1.44
An NKG2D-mediated human lymphoid stress surveillance response with high interindividual variation. Sci Transl Med (2011) 1.33
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst (2009) 1.33
Staphylococcus aureus protein A activates TACE through EGFR-dependent signaling. EMBO J (2007) 1.32
Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol (2009) 1.30
The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res (2009) 1.28
Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem (2010) 1.27
Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science (2012) 1.24
Pore-forming Staphylococcus aureus alpha-toxin triggers epidermal growth factor receptor-dependent proliferation. Cell Microbiol (2006) 1.23
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23
RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med (2012) 1.20
Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol (2012) 1.18
Post-transcriptional control of gene expression by AUF1: mechanisms, physiological targets, and regulation. Biochim Biophys Acta (2012) 1.16
Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol (2005) 1.14
STUDIES ON A METABOLIC DEFECT INDUCED BY HYDROXYUREA (NSC-32065). Cancer Chemother Rep (1964) 1.14
Post-transcriptional gene regulation by MAP kinases via AU-rich elements. Front Biosci (Landmark Ed) (2009) 1.11
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J (1995) 1.11
The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood (2010) 1.09
Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod Pathol (2013) 1.08
FRET-detectable interactions between the ARE binding proteins, HuR and p37AUF1. RNA (2007) 1.08
Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim Biophys Acta (2001) 1.08
Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB J (2013) 1.06
Modulation of neoplastic gene regulatory pathways by the RNA-binding factor AUF1. Front Biosci (Landmark Ed) (2011) 1.06
Role of HuR and p38MAPK in ultraviolet B-induced post-transcriptional regulation of COX-2 expression in the human keratinocyte cell line HaCaT. J Biol Chem (2009) 1.03
NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. J Immunol (2010) 1.02
Functional dissection of hnRNP D suggests that nuclear import is required before hnRNP D can modulate mRNA turnover in the cytoplasm. RNA (2004) 1.01
Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol (2002) 1.01
The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond. Biochim Biophys Acta (2013) 1.01
MIC and other NKG2D ligands: from none to too many. Curr Opin Immunol (2005) 1.00
Combinatorial mRNA binding by AUF1 and Argonaute 2 controls decay of selected target mRNAs. Nucleic Acids Res (2013) 0.99
Stress kinase p38 mediates EGFR transactivation by hyperosmolar concentrations of sorbitol. J Cell Physiol (2002) 0.96
Contribution of intestinal epithelial cells to innate immunity of the human gut--studies on polarized monolayers of colon carcinoma cells. Scand J Immunol (2009) 0.92
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292. Clin Exp Metastasis (2011) 0.90
Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. Neoplasia (2010) 0.89
A disintegrin and metalloproteinase 17 (ADAM17) and epidermal growth factor receptor (EGFR) signaling drive the epithelial response to Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1). J Biol Chem (2012) 0.89
Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection. Surgery (2010) 0.89
UVB radiation induces phosphorylation of the epidermal growth factor receptor, decreases EGF binding and blocks EGF induction of ornithine decarboxylase gene expression in SV40-transformed human keratinocytes. Exp Dermatol (1993) 0.88
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation. J Transl Med (2013) 0.85
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction. Cancer Sci (2011) 0.83
Protective effect of pyruvate against UVB-induced damage in HaCaT human keratinocytes. J Biosci Bioeng (2012) 0.81
UVB irradiation regulates ERK1/2- and p53-dependent thrombomodulin expression in human keratinocytes. PLoS One (2013) 0.80
Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients. Clin Chem (2000) 0.79
Selection of reference genes for gene expression studies in ultraviolet B-irradiated human skin fibroblasts using quantitative real-time PCR. BMC Mol Biol (2011) 0.79
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J Invest Dermatol (1999) 0.78
Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer. Int J Gynecol Cancer (2012) 0.76
In vivo interaction of 4-nitroquinoline-1-oxide and its derivatives with DNA. Nature (1967) 0.76
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol (2011) 5.73
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol (2013) 3.77
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol (2006) 2.50
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet (2008) 2.42
Epithelial decision makers: in search of the 'epimmunome'. Nat Immunol (2010) 2.19
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Maternal health and care-seeking behavior in Bangladesh: findings from a national survey. Int Fam Plan Perspect (2007) 1.84
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol (2010) 1.83
The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science (2011) 1.78
Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol (2005) 1.75
Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics (2008) 1.70
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 1.67
Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol (2004) 1.46
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst (2011) 1.45
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One (2009) 1.44
Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments. Cell (2016) 1.43
Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol (2008) 1.37
Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One (2009) 1.33
Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res (2007) 1.29
Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr Opin Oncol (2011) 1.26
Langerhans cells facilitate epithelial DNA damage and squamous cell carcinoma. Science (2012) 1.24
A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat (2009) 1.23
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res (2014) 1.18
Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res (2011) 1.17
Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes Control (2010) 1.15
Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Mod Pathol (2013) 1.08
Age-dependent requirement for gammadelta T cells in the primary but not secondary protective immune response against an intestinal parasite. J Exp Med (2003) 1.07
Matrix mediates the functional link between human immunodeficiency virus type 1 RNA nuclear export elements and the assembly competency of Gag in murine cells. J Virol (2009) 1.07
Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Hum Mol Genet (2012) 1.06
Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics (2012) 1.03
Therapeutic potential of PARP inhibitors for metastatic breast cancer. Expert Rev Anticancer Ther (2011) 1.02
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov (2011) 1.01
Endogenous MOV10 inhibits the retrotransposition of endogenous retroelements but not the replication of exogenous retroviruses. Retrovirology (2012) 1.00
Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control (2011) 0.97
Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res (2008) 0.96
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics (2013) 0.95
Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur J Cancer (2011) 0.95
Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. J Pathol (2009) 0.95
Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. J Pathol (2010) 0.95
Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy. Radiology (2014) 0.95
Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat (2011) 0.94
HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. J Virol (2012) 0.94
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res (2006) 0.94
Differences in breast cancer hormone receptor status in ethnic groups: a London population. Eur J Cancer (2012) 0.93
A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res (2013) 0.93
γδ T cells are essential effectors of type 1 diabetes in the nonobese diabetic mouse model. J Immunol (2013) 0.92
Comparative Membranome expression analysis in primary tumors and derived cell lines. PLoS One (2010) 0.91
DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference. BMC Bioinformatics (2011) 0.91
PARP inhibitors--current status and the walk towards early breast cancer. Breast (2011) 0.89
Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast Cancer Res (2007) 0.89
Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer (2011) 0.87
Genomic distance entrained clustering and regression modelling highlights interacting genomic regions contributing to proliferation in breast cancer. BMC Syst Biol (2010) 0.87
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. Future Oncol (2010) 0.86
Evolution of a species-specific determinant within human CRM1 that regulates the post-transcriptional phases of HIV-1 replication. PLoS Pathog (2011) 0.86
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res (2006) 0.86
Profiling the immune stromal interface in breast cancer and its potential for clinical impact. Breast Care (Basel) (2012) 0.85
An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Res (2013) 0.85
A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. J Mol Diagn (2009) 0.84
Importance of donor- and recipient-derived selectins in cardiac allograft rejection. J Am Soc Nephrol (2007) 0.84
Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. J Clin Oncol (2011) 0.84
GD₃ synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res (2010) 0.83
Cutting edge: a chemical genetic system for the analysis of kinases regulating T cell development. J Immunol (2003) 0.83
Adjuvant radiotherapy for breast cancer. BMJ (2008) 0.82
MOET: Bangladesh--an initial experience. J Obstet Gynaecol Res (2002) 0.79
Orchestrated leak provokes a thymus reassessment. Nat Immunol (2006) 0.79
Selection and evolution in the genomic landscape of copy number alterations in ductal carcinoma in situ (DCIS) and its progression to invasive carcinoma of ductal/no special type: a meta-analysis. Breast Cancer Res Treat (2015) 0.79
Delineation of a 1Mb breakpoint region at 1p13 in Wilms tumors by fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer (2007) 0.79
Receptor for advanced glycation end products contributes to postnatal pulmonary development and adult lung maintenance program in mice. Am J Respir Cell Mol Biol (2012) 0.79
Provocative exhibits at the Seventeen Gallery. Nat Immunol (2011) 0.78
Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast Cancer Res (2015) 0.78
The 5th EFIS Tatra Immunology Conference on 'Molecular determinants of T cell immunity' held in the High Tatra Mountains, Slovakia, September 7-11, 2002. Immunol Lett (2003) 0.76
Prognostic signatures in breast cancer: correlation does not imply causation. Breast Cancer Res (2012) 0.76